6598 — Applied BioCode Cashflow Statement
0.000.00%
Last trade - 00:00- TWD1.95bn
- TWD1.11bn
- TWD343.07m
Annual cashflow statement for Applied BioCode, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -103 | -165 | -185 | -163 | -261 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -13.9 | 14 | 2.36 | -15 | -28.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -72.9 | -51.6 | 272 | -89.3 | 20.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -147 | -152 | 146 | -205 | -208 |
| Capital Expenditures | -28 | -16.3 | -22.1 | -6.39 | -7.38 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 115 | -0.12 | 0 | -192 | -51.7 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 86.6 | -16.4 | -22.1 | -198 | -59.1 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 657 | -14.2 | -14.9 | -15.7 | 424 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 545 | -202 | 185 | -418 | 193 |